Cardiff Oncology, Inc. – NASDAQ:CRDF
Cardiff Oncology stock price today
$2.32
-2.00
-46.3%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Cardiff Oncology stock price monthly change
+72.11%
month
Cardiff Oncology stock price quarterly change
+72.11%
quarter
Cardiff Oncology stock price yearly change
+184.21%
year
Cardiff Oncology key metrics
Market Cap | 278.71M |
Enterprise value | 51.33M |
P/E | -1.8 |
EV/Sales | 132.98 |
EV/EBITDA | -1.39 |
Price/Sales | 168.30 |
Price/Book | 0.61 |
PEG ratio | 0.08 |
EPS | -0.9 |
Revenue | 610K |
EBITDA | -43.88M |
Income | -40.22M |
Revenue Q/Q | 146.98% |
Revenue Y/Y | 54.43% |
Profit margin | -10026.94% |
Oper. margin | -10337.31% |
Gross margin | 0% |
EBIT margin | -10337.31% |
EBITDA margin | -7193.93% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCardiff Oncology stock price history
Cardiff Oncology stock forecast
Cardiff Oncology financial statements
| Jun 2023 | 108K | -11.15M | -10324.07% |
|---|---|---|---|
| Sep 2023 | 141K | -9.73M | -6901.42% |
| Dec 2023 | 156K | -9.33M | -5985.26% |
| Mar 2024 | 205K | -10.01M | -4883.41% |
| Sep 2025 | 25K | -13.70M | -54800.81% |
|---|---|---|---|
| Oct 2025 | 25K | -13.85M | -55400.72% |
| Dec 2025 | 25K | -13.62M | -54507.16% |
| Mar 2026 | 236.68K | -13.72M | -5796.91% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 327.23% |
|---|---|
| 2020 | 6.45% |
| 2021 | 0.01% |
| 2022 | 0.68% |
| 2023 |
| Jun 2023 | 97455000 | 10.87M | 11.16% |
|---|---|---|---|
| Sep 2023 | 88452000 | 10.62M | 12.01% |
| Dec 2023 | 81637000 | 11.89M | 14.57% |
| Mar 2024 | 74038000 | 13.14M | 17.75% |
| Jun 2023 | -7.13M | 11.48M | -6K |
|---|---|---|---|
| Sep 2023 | -7.95M | 3.82M | -6K |
| Dec 2023 | -7.13M | 13.56M | 12K |
| Mar 2024 | -7.74M | 4.63M | 107K |
Cardiff Oncology alternative data
| Aug 2023 | 25 |
|---|---|
| Sep 2023 | 25 |
| Oct 2023 | 25 |
| Nov 2023 | 25 |
| Dec 2023 | 25 |
| Jan 2024 | 25 |
| Feb 2024 | 25 |
| Mar 2024 | 31 |
| Apr 2024 | 31 |
| May 2024 | 31 |
| Jun 2024 | 31 |
| Jul 2024 | 31 |
Cardiff Oncology other data
6.76%
-11.01%
of CRDF is owned by hedge funds
35
-22
2.94M
-4.75M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2024 | 361615 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PACE GARY W director | Common Stock | 11,500 | $2.6 | $29,900 | ||
Purchase | PACE GARY W director | Common Stock | 350,115 | $2.6 | $910,299 | ||
Purchase | PACE GARY W director | Common Stock | 30,000 | $1.37 | $41,100 | ||
Purchase | ERLANDER MARK director, officer.. | Common Stock | 10,000 | $1.43 | $14,300 | ||
Purchase | WHITE LALE director | Common Stock | 15,000 | $1.64 | $24,525 | ||
Purchase | LEVINE JAMES E. officer: Chief Fi.. | Common Stock | 30,000 | $1.56 | $46,710 | ||
Purchase | PACE GARY W director | Common Stock | 150,000 | $1.71 | $256,500 | ||
Purchase | TANNENBAUM RENEE P director | Common Stock | 3,600 | $1.72 | $6,192 | ||
Purchase | TANNENBAUM RENEE P director | Common Stock | 6,400 | $1.72 | $10,976 | ||
Option | WHITE LALE director | Stock Options | 28,858 | $2.6 | $75,031 |
| Patent |
|---|
Application Filling date: 25 Mar 2020 Issue date: 16 Jun 2022 |
Application ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION Filling date: 25 Feb 2020 Issue date: 12 May 2022 |
Application Filling date: 27 Aug 2021 Issue date: 28 Apr 2022 |
Application Filling date: 24 Aug 2019 Issue date: 22 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2023 3 May 2024 | Q1 2023 Earnings Call Transcript |
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Mark Erlander (1960) Chief Executive Officer & Director | $674,320 |
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity
Cardiff Oncology: Buying The First-Line Onvansertib Strategy
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Cardiff Oncology: Beats Standard Of Care In First-Line Metastatic Colorectal Cancer
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Cardiff Oncology: Down But Not Out
-
What's the price of Cardiff Oncology stock today?
One share of Cardiff Oncology stock can currently be purchased for approximately $2.32.
-
When is Cardiff Oncology's next earnings date?
Unfortunately, Cardiff Oncology's (CRDF) next earnings date is currently unknown.
-
Does Cardiff Oncology pay dividends?
No, Cardiff Oncology does not pay dividends.
-
How much money does Cardiff Oncology make?
Cardiff Oncology has a market capitalization of 278.71M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.42% to 488K US dollars.
-
What is Cardiff Oncology's stock symbol?
Cardiff Oncology, Inc. is traded on the NASDAQ under the ticker symbol "CRDF".
-
What is Cardiff Oncology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cardiff Oncology?
Shares of Cardiff Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cardiff Oncology's key executives?
Cardiff Oncology's management team includes the following people:
- Dr. Mark Erlander Chief Executive Officer & Director(age: 65, pay: $674,320)
-
How many employees does Cardiff Oncology have?
As Jul 2024, Cardiff Oncology employs 31 workers.
-
When Cardiff Oncology went public?
Cardiff Oncology, Inc. is publicly traded company for more then 21 years since IPO on 27 Jul 2004.
-
What is Cardiff Oncology's official website?
The official website for Cardiff Oncology is cardiffoncology.com.
-
Where are Cardiff Oncology's headquarters?
Cardiff Oncology is headquartered at 11055 Flintkote Avenue, San Diego, CA.
-
How can i contact Cardiff Oncology?
Cardiff Oncology's mailing address is 11055 Flintkote Avenue, San Diego, CA and company can be reached via phone at 858 952 7570.
Cardiff Oncology company profile:
Cardiff Oncology, Inc.
cardiffoncology.comExchange:
NASDAQ
Full time employees:
31
Industry:
Biotechnology
Sector:
Healthcare
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
11055 Flintkote Avenue
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001213037
ISIN: US14147L1089
CUSIP: 14147L108
